ADR Reporting Effort Should Focus On Quality, Not Quantity - PhRMA
Executive Summary
Emphasizing the number of adverse drug reaction reports submitted to FDA over the quality of the reports is counterproductive to improving the system, the Pharmaceutical Research & Manufacturers of America maintained at a Feb. 24 Drug Information Association/General Accounting Office forum on postmarketing surveillance in Washington, D.C.